CD8A and neoplasm: A combination vaccine involving irradiated lung adenocarcinoma cells and transfected K562 cells with hCD40L and hGM-CSF induced tumor regression in metastatic lung adenocarcinoma by activating dendritic cells, resulting in a median overall survival of 7.9 months and median progression-free survival of 1.7 months, with 5 out of 14 patients showing CD8+ T-cell activation after vaccination (336).